Incorporating brachytherapy in standard treatment protocols for elderly cervical cancer patients has the potential to improve treatment outcomes, according to a review study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
Smoking and salted vegetable consumption may increase the risk of nasopharyngeal carcinoma (NPC), a recent Singapore study found.
Endoscopic stenting does not up recurrence, mortality risks in patients with obstruction from colorectal cancer
Patients with colorectal cancer who underwent endoscopic stenting for acute large bowel obstruction fared similarly in cancer recurrence risk and overall survival (OS) as those who had emergency surgery, a new study showed.
Circulating micro RNAs (miRNAs) shows good prognostic value for distant metastasis-free survival, relapse-free survival and disease-free survival in patients with triple negative breast cancer, a new meta-analysis shows.
Results of a study suggest that older age and sepsis are linked with higher 1-year overall mortality after colon cancer surgery.
Stratifying ovarian cancer patients with gene expression molecular subtypes (GEMS) enables the identification of AXL in mesenchymal subtype ovarian cancer, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
High neutrophil-to-lymphocyte ratio (NLR) is linked with adverse overall survival (OS) and disease-free survival (DFS) in breast cancer patients, results of a meta-analysis revealed.
Overall survival (OS) improves with adjuvant chemotherapy (AC) after radical nephroureterectomy (RNU) in patients with advanced upper tract urothelial carcinoma (UTUC), experts say.
Asthma may contribute to an added risk of developing myelodysplastic syndrome or chronic myelomonocytic leukaemia (CMML), a recent study suggests.
Baseline 18 F-fluorodeoxyglucose-positron emission tomography (18FDG-PET) indices have prognostic values in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) locally advanced breast cancer, a study shows.